A lymphocyte differentiation and activation antigen, CZ‐1, that distinguishes between CD8+ and unstimulated CD4+ T lymphocytes

M. Vargas‐Cortes,C. L. O’Donnell,M. Appel,J. Maciaszek,Kate S. Yurkunas,R. Welsh
DOI: https://doi.org/10.1002/eji.1830220425
1992-04-01
European Journal of Immunology
Abstract:We report the generation and cellular reactivity of a novel rat IgM monoclonal antibody (mAb), CZ‐1, made against mouse natural killer (NK) cells activated in vivo. mAb CZ‐1 recognizes a molecule whose properties are consistent with that of a trypsin‐sensitive, non‐phosphatidyl inositol‐linked sialoglycoprotein. The expression of the antigen recognized by mAb CZ‐1 is restricted mostly to cells of the lymphoid lineage. The antigen is expressed on 10%–25% of bone marrow cells and 3%–5% of thymocytes. Analysis of thymocyte subpopulations indicates expression of the CZ‐1 antigen on 100% of the NK1.1+, 27% of the CD4−CD8−, 1.1% of the CD4+CD8+, 1.1% of the CD4+CD8−, and 33% of the CD4−CD8+ cells. In the spleen, the CZ‐1 antigen is expressed on B lymphocytes, NK cells, and virtually all CD8+ T lymphocytes. Most unstimulated CD4+ splenic T lymphocytes, monocytes and polymorphonuclear cells, with the notable exception of basophils, do not react with mAb CZ‐1. CD4+ T cells activated in vivo by virus infection or in vitro by anti‐CD3 and interleukin‐2 express the CZ‐1 antigen. These results indicate that mAb CZ‐1 identifies a novel inducible lymphocyte activation/differentiation antigen that distinguishes between thymic and unstimulated splenic CD4+ and CD8+ T lymphocytes. This mAb will be a useful tool in the identification of lymphocyte subpopulations and in the study of the ontogeny and activation of these cells.
What problem does this paper attempt to address?